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Abstract  
Complementary and alternative medicine (CAM) use is common among patients with chronic diseases in developing countries. The rising use of 
CAM in the management of diabetes is an emerging public health concern given the potential adverse effects, drug interactions and benefits 
associated with its use. Herbal medicine, dietary supplements, prayers and relaxation techniques are some of the most frequently used CAM 
modalities  in  Kenya.  Cited  reasons  for  CAM  use  as  adjuvant  therapy  include  dissatisfaction  and  inaccessibility  of  allopathic  medicine,  and 
recommendations by family and friends. This article explores the pattern of CAM use in Kenya and other developing countries. It also identifies 
some constraints to proper CAM control, and offers suggestions on what can be done to ensure safe and regulated CAM use.  
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Introduction 
 
The prevalence of diabetes mellitus (DM) worldwide is projected to 
rise to 552 million (representing 10% of the global adult population) 
by 2030 up from 366 million in 2011 [1]. The burden is worse in the 
developing world which represents over 80% of cases [1, 2].  
  
In DM management, lifestyle measures, oral glucose-lowering drugs 
and  insulin  are  the  conventional  therapies.  The  latter  two  are, 
however,  expensive  or  even  unavailable  to  many  patients  in 
developing  countries  [3],  and  are  sometimes  associated  with 
adverse  effects  [4].  Consequently,  some  patients  opt  for 
complementary  and  alternative  medicine  (CAM)  to  manage  their 
DM. The prevalence of CAM use among people living with DM is 
estimated to be as high as 80% in Africa [5, 6].  
  
  
Pattern of CAM use in Africa 
 
Commonly  used  CAM  therapies  among  diabetic  patients  in  Africa 
include herbal medicines, nutritional products, spiritual healing and 
relaxation techniques [7-10]. These CAM therapies are extensively 
used by patients as adjuvant or as replacement treatment to the 
conventional  prescribed  drugs  [11-14].  CAM  use  in  Africa  is 
amplified by the presence of traditional healers, with estimates of 
one  traditional  healer  present  to  every  200  people  [15].  These 
traditional  healers  make  selective  use  of  CAM,  biomedical 
knowledge and language to enhance the perceived effectiveness of 
their treatments [15].  
  
The use of CAM in Africa has been associated with cultural beliefs, 
age of patient, duration of DM, degree of complications, and advice 
from  family  and  friends  [16,  17].  Most  importantly,  the 
inaccessibility and shortcomings in conventional healthcare provision 
in Africa contribute to the high use of CAM [3].  
  
A  major  concern  is  that  diabetic  patients  may  replace  clinically 
proven conventional diabetes treatments with CAM agents [18, 19]. 
These  patients  rarely  disclose  their  CAM  practices  to  their  health 
care  providers  (HCPs)  [20],  an  issue  which  warrants  particular 
attention. There is a potential risk of drug interaction when these 
agents are used as adjuvants to allopathic medicine. They may also 
interfere negatively with glycemic control, and cause adverse effects 
and additional complications [6, 15, 19, 21]. It is a well-known fact 
that  most  CAM  agents  contain  active  ingredients  for  which 
appropriate doses and side effects have not been determined. They 
are therefore likely to be administered at inconsistent doses, with 
the potential for fatal health effects and mortalities [17].  
  
  
Challenges in controlling CAM in Africa 
 
A number of constraints exist in the control of CAM use in Africa. 
For  instance,  there  is  lack  of  integration  of  CAM  therapies  into 
African mainstream health care systems. This is despite the World 
Health  Organization  (WHO)  recommendation  to  "integrate 
traditional and CAM therapies into national health care systems" [6].  
  
Another major concern is the lack of regulation on CAM use in Africa 
and  other  developing  countries,  and  therefore  exposing  the 
population to potential harm. There exists limited quality assurance 
with  most  CAM  regulatory  processes  falling  outside  the  scope  of 
most  government  drug  and  therapeutic  agencies  in  Africa.  For 
instance,  the  registration  of  herbalists  in  Kenya  is  done  by  the 
Ministry of Social services, but in essence most of  the traditional 
herbalists are not even aware of this.  
  
There is also limited research on CAM use by people with diabetes 
in developing countries including Kenya. Some CAM products may 
also be beneficial and safe; but the lack of randomized controlled 
trials makes their use controversial [21].  
  
HCPs are also not aware that so many of their diabetic patients use 
CAM  therapies.  HCPs  should  therefore  have  this  in  mind,  and 
routinely take a thorough history to document any such therapies 
and discuss these practices with their patients in order to safeguard 
their health. HCPs should educate their patients on the importance 
of adherence, controlling blood sugars and avoidance of potentially 
dangerous CAM.  
  
  
Conclusion 
 
CAM  is  widely  used  among  diabetic  patients  as  an  adjunct  to 
conventional  therapy  in  developing  countries.  This  could  result  in 
ineffective  diabetes  management  and  cause  adverse  effects, Page number not for citation purposes  3 
especially since the CAM use is rarely disclosed to HCPs. Empirical 
evidence, integration and stringent national regulatory safe-guards 
should  guide  the  safe  and  appropriate  CAM  use  and  sales. 
Legislation to govern CAM use is therefore necessary and inevitable. 
Above  all,  conventional  medications  should  be  easily  accessible. 
HCPs should also be aware of CAM use, and educate their patients 
accordingly.  There  is  a  need  for  urgent  multi-sectorial  action  to 
streamline CAM use among patients in Africa and other developing 
countries.  
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